Thrombocytosis in gynecologic malignancies

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 2053-2059

  Gücer, Fatih ^a   Tamussino, K ^b   Keil, F ^c   Balkanli Kaplan, P ^a   Yuce M A ^a  

^a TRAKYA UNIVERSITY   (Turkey)

^b UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cervical carcinoma; Endometrial carcinoma; Ovarian cancer; Platelet count; Thrombocytosis

Indexed keywords

DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HEALTH SURVEY; HUMAN; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTE RELEASE REACTION; THROMBOCYTOSIS; UTERINE CERVIX CANCER; VULVA CANCER;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; PROGNOSIS; THROMBOCYTOSIS;

EID: 3242729590     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Riess L: Zur pathologischen Anatomie des Blutes. Arch Anat Physiol Wissensch Med 39: 237-249, 1872.
2. Costantini V, Zacharski LR, Moritz TE and Edwards RL: The platelet count in carcinoma of the lung and colon. Thromb Haemost 64: 501-505, 1990.
3. Nakano T, Fujii J, Tamura S, Hada T and Higashino K: Thrombocytosis in patients with malignant mesothelioma. Cancer 58: 1699-1701, 1986.
4. Hernandez E, Lavine M, Dunton CJ, Gracely E and Parker J: Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 69: 2975-2977, 1992.
5. Rodriguez GC, Clarke-Pearson DL, Soper JT, Berhuck A, Synan I and Dodge RK: The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecol 83: 445-448, 1994.
6. Moller-Pedersen L and Milman N: Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 9: 1826-1830, 1996.
7. Zeimet AG, Marth C, Muller-Holzner E, Daxenbichler G and Dapunt O: Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 170: 549-554, 1994.
8. Levin J and Conley CL: Thrombocytosis associated with malignant disease. Arch Int Med 114: 497-500, 1964.
9. Espanol I, Hernandez A, Cortes M, Mateo J and Pujol-Moix N: Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels. Haematologica 84: 312-316, 1999.
10. Corbet G and Perry DJ: Significance of thrombocytosis. Lancet 1: 77, 1983.
11. von Knorring J, Selroos O and Scheinin TM: Haematologic findings in patients with renal carcinoma. Scand J Urol Nephrol 15: 279-83, 1981.
12. Dutcher JA: Hematologic abnormalities in patients with nonhematologic malignancies. Hematol Oncol Clin North Am 1: 281-99, 1987.
13. Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, Cornell CJ, Forcier RJ, O'Donnel JF and Headley E: Abnormalities of blood coagulation tests in patients with cervical cancer. Am J Clin Pathol 88: 596-602, 1988.
14. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH and Rubin SC: High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 83: 433-41, 1993.
15. Obata NH, Tamakoshi K, Shibata K, Kikkawa F and Tomoda Y: Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 17: 337-342, 1997.
16. Erroi A, Sironi M, Chiaffarino F, Zhen-Guo, Mengozzi M and Mantovani A: IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma. Int J Cancer 44: 795-801, 1989.
17. Estrov Z, Talpaz M, Mavligit G, Pazdur D, Harris D, Greenberg SM and Kurzrock R: Elevated plasma thrombopoietic activity in patients with metastatic cancer related thrombocytosis. Am J Med 98: 551-8, 1995.
18. Dan K, Gomi S, Inokuchi K, Ogata K, Yamada T, Ohki I, Hasegawa S and Nomura T: Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Acta Haematol 93: 67-72, 1995.
19. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E and Dirix LY: Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 80: 892-7, 1999.
20. Imai T, Koike K, Kubo T, Kikuchi T, Amano Y, Okumuro N and Nakahata T: Interleukin-6 supports human megakaryocyte proliferation and differentiation in vitro. Blood 78: 1969-74, 1991.
21. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T et al: Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74: 1241-44, 1989.
22. Watson JM, Sensintaffar JL, Berek JS and Martinez-Maza O: Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cell cultures. Cancer Res 50: 6959-65, 1990.
23. Serve H, Steinhauser G, Oberberg D, Flegel WA, Northoff H and Berdel WE: Studies on the interactions between interleukin-6 and human malignant nonhematopoietic cell lines. Cancer Res 51: 3862-6, 1991.
24. Guillame T, Sekhavat M, Rubinstein DB, Hamdan O and Symann ML: Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3 and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines. Cancer Res 53: 3139-44, 1993.
25. Van der Zee AGJ, De Cuyper EMJ, Limburg PC, De Bruijn HWA, Hollema H, Bijzet J, Krans M and De Vires EGE: Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer 75: 1004-9, 1995.
26. Van Gameren MM, Willemse PHB; Mulder NH, Limburg PC, Groen HJM, Vellenga E et al: Effects of recombinant human interleukin-6 in cancer patients; a phase I-II study. Blood 84: 1434-41, 1994.
27. D'Hondt V, Humblet Y, Guillame T, Baatout S, Chatelain C and Berliere M: Thrompopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicenter placebo-controlled randomized phase Ib study. Blood 85: 2347-53, 1995.
28. Weber J, Yang JC, Topalian SL, Schwartzentruber DS, Ettinghausen SE, Gunn H et al: Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 11: 499-504, 1993.
29. Eustace D, Han X, Gooding R, Rowbottom A, Riches P and Heyderman E: Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 50: 15-9, 1993.
30. Iglesias M, Plowman GD and Woodworth CD: Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirus- immortalized and carcinoma-derived cervical cells in vitro. Am J Pathol 146: 944-52, 1995.
31. Castrilli G, Tatone D, Diodoro MG, Rosini S, Piantelli M and Musiani P: Interleukin 1alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. Br J Cancer 75: 855-9, 1997.
32. Facchini V and Bianchi R: Serum interleukin-6 levels in uterine malignancies. Preliminary data. Anticancer Res 14: 735-7, 1994.
33. Chopra V, Dinh TV and Hannigan EV: Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 16: 152-9, 1998.
34. Tjong MY, Van der Vange N, ten Kate FJ, Tjong-A-Hung SP, ter Schegget J, Burger MP and Out TA: Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol 73: 285-91, 1999.
35. Chopra V, Dinh TV and Hannigan EV: Serum levels of interleukins, growth factors and angiogenin in patients with endometrial carcinoma. J Cancer Res Clin Oncol 123: 167-172, 1997.
36. Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M, Amoroso M, Mascuillo V, Peschle G and Mancuso S: Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 57: 318-23, 1994.
37. Sowade O, Ziemer S, Sowade B, Franke W, Messinger D, Ziebell E, Scigalla P and Warnke H: The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery. J Lab Clin Med 129: 376-83, 1997.
38. Biesma DH, Marx JJ, Kraaijenhagen RJ, Franke W, Messinger D and van de Wiel A: Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet 344: 367-70, 1994.
39. Honn KV, Tang DG and Crissman JD: Platelets and cancer metastasis: A causal relationship. Cancer Metastasis Rev 11: 325-41, 1992.
40. Qian X and Tuszynski GP: Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med 212: 199-207, 1996.
41. Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA and Gasic GJ: Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 47: 4130-3, 1987.
42. Karpatkin S and Pearlstein E: Role of platelets in tumor cell metastases. Ann Intern Med 95: 636-41, 1981.
43. Pearlstein E, Ambrogio C and Karpatkin S: Effect of antiplatelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma and B16 amelonotic melanoma tumor cells into mice. Cancer Res 44: 3884-7, 1984.
44. Zabrenetzky VS, Kohn EC and Roberts DD: Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide. Cancer Res 50: 5937-42, 1990.
45. Francis JL, Biggerstaff J and Amirkhosravi A: Hemostasis and malignancy. Semin Thromb Hemost 24: 93-109, 1998.
46. Hejna M, Raderer M and Zielinski CC: Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91: 22-36, 1999.
47. Nathan FE, Hernandez E, Dunton CJ, Treat J, Switalska HI, Josef JJ and Tuszynski GP: Plasma thrombospondin levels in patients with gynecological malignancies. Cancer 73: 2853-8, 1994.
48. Chalas E, Welshinger M, Engellener W, Chumas J, Barbieri R and Mann WJ: The clinical significance of thrombocytosis in women presenting with a pelvic mass. Am J Obstet Gynecol 166: 974-7, 1992.
49. Hakverdi AU, Yayla M, Göcmen A, Gül T, Erden AC and Demiroglu S: The clinical significance of preoperative serum CA-125 levels and thrombocytosis in patients with pelvic mases. Jinekoloji ve Obstetrik Dergisi 9: 205-9, 1995.
50. den Ouden M, Ubachs JM, Stoot JE and van Wersch JW: Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol 72: 73-7, 1997.
51. Kerpsack JT and Finan MA: Thrombocytosis as a predictor of malignancy in women with a pelvic mass. J Reprod Med 45: 929-32, 2000.
52. Menczer J, Schejter E, Geva D, Ginath S and Zakut H: Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Obstet 19: 82-4, 1998.
53. Li AJ, Madden AC, Cass I, Leuchter RS, Lagasse LD and Karlan BY: The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol 92: 211-14, 2004.
54. Lund B and Williamson P: Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian cancer. Obstet Gynecol 76: 617-22, 1990.
55. Obermair A, Handisurya A, Kaider A, Sevelda P, Kölbl H and Gitsch G: The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer 83: 726-31, 1998.
56. Kappen HJ and Neijt JP: Neural network analysis to predict treatment outcome. Annal Oncol 4 (Suppl. 4): S31-S34, 1993.
57. Nather A, Mayerhofer K, Grimm C, Hefler L, Leodolter S, Obermair A and Joura EA. Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy. Anticancer Res 23: 2991-4, 2003.
58. Lopes A, Daras V, Cross PA, Robertson G, Beynon G and Monaghan JM: Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 74: 90-2, 1994.
59. Hernandez E, Heller PB, Whitney C, Diana K and Delgado G: Thrombocytosis in surgically treated stage IB squamous cell cervical carcinoma (a Gynecologic Oncology Group study). Gynecol Oncol 55: 328-32, 1994.
60. Gücer F, Tamussino K, Panzitt T, Taucher A, Haas J, Petru E and Winter R: Prognostic implications of thrombocytosis in patients with stage III and IV cervical cancer. Int J Gynecol Cancer 8: 369-73, 1998.
61. Hernandez E, Donohue KA, Anderson LL, Heller PB and Stehman FB: The significance of thrombocytosis in patients with locally advanced cervical carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 78: 137-42, 2000.
62. Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ and Pringle JF: Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37: 302-6, 1978.
63. Hong JH, Chen MS, Lin FJ and Tang SG: Prognostic assessment of tumor regression after external irradiation for cervical cancer. Int J Radiat Oncol Biol Phys 22: 913-7, 1992.
64. Hockel M, Vorndran B, Schlenger K, Bausmann E and Knapstein PG: Tumor oxygenation: A new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 51: 141-9, 1993.
65. Grogan M, Thomas GM, Melamed I, Wong FLW, Pearcey RG, Joseph PK, Portelance L, Crook J and Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528-36, 1999.
66. Gücer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G et al.: Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol 70: 210-4, 1998.
67. Menczer J, Geva D, Schejter E and Zakut H: Elevated platelet count in patients with endometrial carcinoma: correlation with selected prognostic factors and with survival. Int J Gynecol Cancer 6: 463-6, 1996.
68. Scholz HS, Petru E, Gücer F, Haas J, Tamussino K and Winter R: Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res 20: 3983-5, 2000.
69. Tamussino KF, Gucer F, Reich O, Moser F, Petru E and Scholz HS: Pretreatment hemoglobin, platelet count and prognosis in endometrial carcinoma. Int J Gynecol Cancer 11: 236-40, 2001.
70. Lavie O, Comerci G, Daras V, Bolger BS, Lopes A and Monaghan JM: Thrombocytosis in women with vulvar carcinoma. Gynecol Oncol 72: 82-6, 1999.
71. Hefler L, Mayerhofer K, Leibman B, Obermair A, Reinthaller A, Kainz C and Tempfer C: Tumor anemia and thrombocytosis in patients with vulvar cancer. Tumour Biol 21: 309-14, 2000.
72. Dabrow MB, Francesco MR, McBrearty FX and Caradonna S: The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 71: 29-37, 1998.